CompletedPHASE1, PHASE2NCT01465659
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Studying Neuroendocrine carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Northwestern University
- Principal Investigator
- Halla Nimeiri, M.DNorthwestern University
- Intervention
- temozolomide(drug)
- Enrollment
- 29 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2021
Study locations (5)
- Northwestern University, Chicago, Illinois, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Vanderbilt University, Nashville, Tennessee, United States
- University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States
Collaborators
Robert H. Lurie Cancer Center · National Comprehensive Cancer Network · GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01465659 on ClinicalTrials.govOther trials for Neuroendocrine carcinoma of pancreas
Additional recruiting or active studies for the same condition.